XIST loss impairs mammary stem cell differentiation and increases tumorigenicity through Mediator hyperactivation

Archive ouverte

Richart, Laia | Picod-Chedotel, Mary-Loup | Wassef, Michel | Macario, Manon | Aflaki, Setareh | Salvador, Marion | Héry, Tiphaine | Dauphin, Aurélien | Wicinski, Julien | Chevrier, Véronique | Pastor, Sonia | Guittard, Geoffrey | Le Cam, Samuel | Kamhawi, Hanya | Castellano, Rémy | Guasch, Géraldine | Charafe-Jauffret, Emmanuelle | Heard, Edith | Margueron, Raphaël | Ginestier, Christophe

Edité par CCSD ; Elsevier -

International audience. X inactivation (XCI) is triggered by upregulation of XIST, which coats the chromosome in cis, promoting formation of a heterochromatic domain (Xi). XIST role beyond initiation of XCI is only beginning to be elucidated. Here, we demonstrate that XIST loss impairs differentiation of human mammary stem cells (MaSCs) and promotes emergence of highly tumorigenic and metastatic carcinomas. On the Xi, XIST deficiency triggers epigenetic changes and reactivation of genes overlapping Polycomb domains, including Mediator subunit MED14. MED14 overdosage results in increased Mediator levels and hyperactivation of the MaSC enhancer landscape and transcriptional program, making differentiation less favorable. We further demonstrate that loss of XIST and Xi transcriptional instability is common among human breast tumors of poor prognosis. We conclude that XIST is a gatekeeper of human mammary epithelium homeostasis, thus unveiling a paradigm in the control of somatic cell identity with potential consequences for our understanding of gender-specific malignancies.

Suggestions

Du même auteur

EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition

Archive ouverte | Romero, Pierre | CCSD

International audience. Mutations in chromatin regulators are widespread in cancer. Among them, the histone H3 lysine 27 methyltransferase Polycomb Repressive Complex 2 (PRC2) shows distinct alterations according to...

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells

Archive ouverte | Arfaoui, Abir | CCSD

International audience. Therapeutic resistance is a major clinical challenge in oncology. Evidence identifies cancer stem cells (CSCs) as a driver of tumor evolution. Accordingly, the key stemness property unique to...

BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells

Archive ouverte | Azzoni, Violette | CCSD

International audience. Abstract Replication stress (RS) has a pivotal role in tumor initiation, progression, or therapeutic resistance. In this study, we depicted the mechanism of breast cancer stem cells’ (bCSCs) ...

Chargement des enrichissements...